Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting
08 mars 2022 16h35 HE
|
Beyond Air™
GARDEN CITY, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022
10 févr. 2022 16h05 HE
|
Beyond Air™
LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised...
Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022
08 févr. 2022 08h00 HE
|
Beyond Air™
GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors
03 févr. 2022 16h05 HE
|
Beyond Air™
Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk...
Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast
27 janv. 2022 08h00 HE
|
Beyond Air™
GARDEN CITY, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Provides Regulatory Update for LungFit® PH
09 déc. 2021 08h30 HE
|
Beyond Air™
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer
01 déc. 2021 08h00 HE
|
Beyond Air™
Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120...
Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placement
18 nov. 2021 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022
11 nov. 2021 16h05 HE
|
Beyond Air™
U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth...
Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors
04 nov. 2021 07h30 HE
|
Beyond Air™
$23.9 million committed in concurrent equity private placement to form Beyond Cancer that will leverage Beyond Air’s nitric oxide (NO) expertise and take over development of current solid tumor...